Drugs / KarX-EC
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07285798 | Sep 2026 → Aug 2029 expected | autism spectrum disorder | Bristol-Myers Squibb | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06947941 | Mar 2026 → Feb 2028 expected | Alzheimer disease, psychotic disorder | Bristol-Myers Squibb | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06976203 Comparator | Jul 2025 → Sep 2028 expected | Alzheimer disease | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 3 | NCT06976216 Comparator | Jul 2025 → Sep 2028 expected | Alzheimer disease | Bristol-Myers Squibb | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KarX-EC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06976216 ↗ |